Safety And Efficacy Of Bosutinib

• Status: Recruiting
• Trial end date: 2023-08-07
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this surveillance is to collect information about

1. adverse drug reaction not expected from the LPD (unknown adverse drug reaction)

2. the incidence of adverse drug reactions in this surveillance

3. factors considered to affect the safety and/or efficacy of this drug.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Chronic myelogenous leukemia patients resistant or intolerant to prior treatment there is no experience with this drug

• Newly-diagnosed chronic phase Chronic myelogenous leukemia patients there is no experience with this drug

Exclusion Criteria:

• Patients with a history of hypersensitivity

• Women who may possibly be pregnant or become pregnant